The prolific company creator is staking $50 million on AI drug discovery for cancer and immune diseases, launching a biotech ...
FMC-376 demonstrated robust anti-tumor activity across preclinical models and led to deeper inhibition of KRAS downstream ...
US pharma major Pfizer (NYSE: PFE) has selected newly launched Expedition Medicines, a Flagship Pioneering company, as its ...
Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today unveiled Expedition Medicines™, a company pioneering generative covalent chemistry to expand the ...
Modern chemistry is increasingly focused on developing sustainable processes that reduce energy consumption and minimize ...
Expedition Medicines has emerged from stealth with $50 million in funding from Flagship Pioneering. The start-up uses ...
Beta-blockers are widely prescribed pharmaceuticals used to manage cardiovascular conditions such as hypertension, ...
FMC-242 is a potentially best-in-class covalent allosteric inhibitor that breaks the interaction between PI3Kα and RAS, ...
Science publication describes the discovery and preclinical characterization of small molecules that inhibit RAS-dependent PI3K oncogenic signaling.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback